News & Updates

Shorter treatment regimen feasible for rifampin-resistant TB?
Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023 byAudrey Abella

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
11 Feb 2023
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
11 Feb 2023